Moderna’s previously booming stock price took a major hit on Wednesday, falling more than 15 per cent after an analyst warned that the company’s valuation was “unrealistic”, and unjustifiably inflated due to hype around the company’s COVID vaccine.
It marks the continuation of a concerning week for investors in the stock, as the losses continued for the second day in a row.
The drop seems to have been precipitated by the harsh analysis of Bank of America’s Geoff Meacham, who on Monday called the company’s valuation “ridiculous”, and “unjustifiable”.
For the company to meet his price target, shares would need to slide more than 75 per cent against prices on Monday.
Shares in competing vaccine manufacturer, BioNTech, were also down this week, but seemingly due to an opposing reason, as a US study showed that its vaccine, developed in collaboration with Pfizer, might be less effective against battling the Delta variant of COVID.
Two new studies of over 50,000 patients in the Mayo Clinic Health System showed that Moderna’s vaccine might actually be more effective against the more transmissible variant of the virus.
It found that the effectiveness of the BioNTech’s vaccine in preventing infection with the variant was only 42 per cent in July, compared to 76 per cent for Moderna’s.
Ryanair cuts Malta link to Serbia’s Niš
The low-cost airline is slashing some major routes in Germany, Spain, Belgium, Portugal and Malta
Event tourism is the standout travel trend for 2026 – How will Malta fare?
The global tourism market is booming, and events are leading the way
EU Parliament agrees on common system to calculate corporations’ taxable income
The reform is designed to replace today’s patchwork of national tax rule